Skip directly to content

Publications 1992

Addthis

2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992

AIDS Research at the NIH: A Critical Review
Part I: Summary

By Gregg Gonsalves and Mark Harrington
VIII International Conference on AIDS, Amsterdam, the Netherlands, July 20, 1992

Since 1987, the activist critique of AIDS research has worked its way back: from drug approval at the regulatory level of the US Food & Drug Administration (FDA), to expanded access for drugs still under study (Parallel Track), to the design and conduct of the controlled clinical trials themselves by the National Institutes of Health (NIH), pharmaceutical companies and, community-based clinical trial centers. While this work has generated some useful reforms in an inefficient system (and expanded access and expedited approval for several useful therapies), it often seems that all these accomplishments go for naught. HIV keeps spreading, AIDS keeps striking people down, and researchers appear to have little confidence in the rapid development of a therapeutic cure or an effective vaccine.

AIDS Research at the NIH: A Critical Review
Part II: The NIH, A User's Guide

By Gregg Gonsalves and Mark Harrington
VIII International Conference on AIDS, Amsterdam, the Netherlands, July 20, 1992

The NIH, A User's Guide, is the final section of our report on the AIDS programs of the National Institutes of Health. The material contained here is summarized, under separate cover, in Part I. We have provided this unexpurgated sourcebook as a tool for AIDS activists and advocates and others who want to learn about the AIDS programs sponsored by each of the institutes and centers at NIH in greater detail than is offered in our summary. You will find in the following pages: brief histories of each of the institutes and their AIDS funding, including the evisceration of the fiscal year 1993 AIDS budget; descriptions of each of their extramural and intramural programs, often with the principal investigators and their institutions listed; the "wish lists" of new programs and expansions of existing ones each institute would have liked to initiate for fiscal year 1993; and the lists of our recommendations for each fo the institutes, the NIH and Congress and the President.

PATHOGENESIS + ACTIVISM
Speech by Mark Harrington
Presented at VIII International Conference on AIDS, Amsterdam, July 21, 1992

This morning, I'm going to talk about where we in the AIDS community stand after five years of relentless treatment activism, why we need to change, and how you - the researchers and clinicians working full-time on AIDS and HIV infection - can help us to find out what we need to know and do.